Argent BioPharma's Strategic Acquisition: Aiming for a $100M Valuation with AusCann Group Assets Argent BioPharma is set to acquire key assets from AusCann Group, enhancing its clinical pipeline and European presence. The move anticipates a company valuation of $100M.

Argent BioPharma's Strategic Acquisition: Aiming for a $100M Valuation with AusCann Group Assets #Australia #Sydney #Argent_BioPharma #AusCann_Group #Neuvis

Argent BioPharma Expands into Germany's Largest Pharmaceutical Market Argent BioPharma has officially entered Germany's pharmaceutical market, making significant strides with regulatory approvals and operational cost savings.

Argent BioPharma Expands into Germany's Largest Pharmaceutical Market #Germany #Berlin #Argent_BioPharma #CannEpil #CogniCann

Argent BioPharma's Significant Breakthrough with CimetrA® in Treating Inflammatory Disorders Argent BioPharma Ltd. announces promising Phase IIb results for CimetrA®, an innovative anti-inflammatory drug, potentially revolutionizing treatment options.

Argent BioPharma's Significant Breakthrough with CimetrA® in Treating Inflammatory Disorders #Australia #Argent_BioPharma #Perth #CimetrA® #CannEpil®

Argent BioPharma's Groundbreaking Initiatives in Chronic Wound Care Collaboration with SINTEF Argent BioPharma Ltd. makes strides in its collaboration with SINTEF focusing on innovative antimicrobial solutions for chronic wound management, targeting market needs.

Argent BioPharma's Groundbreaking Initiatives in Chronic Wound Care Collaboration with SINTEF #Australia #Argent_BioPharma #Perth #SINTEF #Chronic_Wounds

Argent BioPharma Secures $4.5 Million to Advance Innovative Therapeutics Argent BioPharma has successfully raised $4.5 million to propel their groundbreaking work in neuro-immune modulation for CNS disorders.

Argent BioPharma Secures $4.5 Million to Advance Innovative Therapeutics #Australia #Argent_BioPharma #CannEpil #Perth #neuro-immunology

Argent BioPharma's US$4.5 Million Capital Raise to Advance Innovative Treatments Argent BioPharma has successfully raised US$4.5 million to enhance its drug development pipeline for CNS and immune-related disorders. The funds will boost clinical studies and operations.

Argent BioPharma's US$4.5 Million Capital Raise to Advance Innovative Treatments #Australia #Argent_BioPharma #Nano-medicine #CannEpil #Perth